Results 21 to 30 of about 14,917 (287)

Renoprotective Effects of Edaravone in a Model of Acute kidney Injury Induced by Rhabdomyolysis in Rats, the Involvement of Nitric oxide [PDF]

Trends in Pharmaceutical Sciences, 2022
Edaravone is a free radical scavenger which is used as a drug for the treatment of cerebral infarction and amyotrophic lateral sclerosis. Edaravone is distributed widely in the body and its effects are not limited to the neural tissue.
Leila Moezi, Mohammad Reza Panjehshahin, Simin Torabinezhad, Eskandar Kamali-Sarvestani, Shirin Farjadian, Fatema Pirsalami, Azin Ebrahimpour, Somayeh Oftadehgan, Azar Purkhosrow, Maryam Mojahedtaghi, Elahe Sattarinezhad   +10 more
doaj   +1 more source

Synthesis of two metabolites of edaravone [PDF]

Journal of Chinese Pharmaceutical Sciences, 2010
Xin-Rong Zhu, Yong-Qaing Zhu
openalex   +2 more sources

Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomised controlled trial. [PDF]

Stroke Vasc Neurol
Background Edaravone dexborneol is believed to be a novel cytoprotective drug, demonstrating a synergistic combination of antioxidative and anti-inflammatory properties in animal models.
Wang C, Gu HQ, Dong Q, Xu A, Wang N, Yang Y, Wang F, Wang Y.   +7 more
europepmc   +2 more sources

Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway

Journal of Neuroinflammation, 2021
Background The inflammation and oxidative stress (OS) have been considered crucial components of the pathogenesis of depression. Edaravone (EDA), a free radical scavenger, processes strong biological activities including antioxidant, anti-inflammatory ...
Ruozhi Dang, Mingyang Wang, Xinhui Li, Haiyang Wang, Lanxiang Liu, Qingyuan Wu, Jianting Zhao, P. Ji, Lianmei Zhong, J. Licinio, P. Xie   +10 more
semanticscholar   +1 more source

Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. [PDF]

PLoS ONE, 2014
BACKGROUND: Many of these therapies have been compared against placebos, but have not been directly compared against each other. To evaluate the efficacy and safety of several commonly used drugs for AIS directly or indirectly.
Bowen Yang, Jingpu Shi, Xin Chen, Bing Ma, Hao Sun   +4 more
doaj   +1 more source

Sustained Release of Neuroprotective Drugs Curcumin and Edaravone from Supramolecular Hydrogel for Ischemic Stroke Treatment

Advanced Functional Materials, 2023
Ischemic stroke is a major cause of death and disability worldwide. The poor drug delivery to cerebral ischemic regions remains a challenging issue for ischemic stroke treatment.
Yan-peng Jia, Yi Zhang, Wenjun Zhan, Yu Wang, Xianbao Sun, Yuan Zhang, Xiaoyang Liu, Bing Han, Ying Bai, Ling Shen, G. Liang, Honghong Yao   +11 more
semanticscholar   +1 more source

Acute and Sub-chronic Anticonvulsant Effects of Edaravone on Seizure Induced by Pentylenetetrazole or Electroshock in Mice, Nitric Oxide Involvement [PDF]

Iranian Journal of Medical Sciences, 2023
Background: Edaravone is an anti-stroke medication that may have nitric oxide (NO) modulating properties. This study evaluated the role of NO in the acute and sub-chronic anticonvulsant effects of edaravone in murine models of seizures induced by ...
Leila Moezi, Fatema Pirsalami, Mona Dastgheib, Somayeh Oftadehgan, Azar Purkhosrow, Elahe Sattarinezhad   +5 more
doaj   +1 more source

Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.

JAMA Neurology, 2022
Importance Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in ...
S. Witzel, A. Maier, R. Steinbach, J. Grosskreutz, J. Koch, Anastasia Sarikidi, S. Petri, R. Günther, Joachim Wolf, A. Hermann, J. Prudlo, I. Cordts, P. Lingor, W. Löscher, Z. Kohl, T. Hagenacker, C. Ruckes, B. Koch, S. Spittel, Kornelia Günther, S. Michels, J. Dorst, T. Meyer, A. Ludolph   +23 more
semanticscholar   +1 more source

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]

, 2017
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat, Applegate, Richard, Araujo, Camila, Ho, Wing Mann, Huang, Lei, Reis, Cesar, Zhang, John H   +6 more
core   +7 more sources

Formulary Drug Review: Edaravone [PDF]

Hospital Pharmacy, 2017
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker, Zaynah K. Ali
openaire   +3 more sources